A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced NSCLC with EGFR or HER2 Mutation. This evidence concerns the gene ERBB2 and neoplasm.